Cargando…

The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink

To estimate the incidence, prevalence, and survival of systemic sclerosis in the United Kingdom. We conducted a historical cohort study using data from the Clinical Practice Research Datalink (CPRD). We calculated the incidence and survival of systemic sclerosis between 1994 and 2013 and examined it...

Descripción completa

Detalles Bibliográficos
Autores principales: Royle, Jeremy G., Lanyon, Peter C., Grainge, Matthew J., Abhishek, Abhishek, Pearce, Fiona A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061074/
https://www.ncbi.nlm.nih.gov/pubmed/29961234
http://dx.doi.org/10.1007/s10067-018-4182-3
_version_ 1783342144982876160
author Royle, Jeremy G.
Lanyon, Peter C.
Grainge, Matthew J.
Abhishek, Abhishek
Pearce, Fiona A.
author_facet Royle, Jeremy G.
Lanyon, Peter C.
Grainge, Matthew J.
Abhishek, Abhishek
Pearce, Fiona A.
author_sort Royle, Jeremy G.
collection PubMed
description To estimate the incidence, prevalence, and survival of systemic sclerosis in the United Kingdom. We conducted a historical cohort study using data from the Clinical Practice Research Datalink (CPRD). We calculated the incidence and survival of systemic sclerosis between 1994 and 2013 and examined its association with age, sex, and socioeconomic status. We calculated point prevalence on 1 July 2013 and examined its association with the same exposures. We identified 1327 cases with incident systemic sclerosis. Annual incidence was 19.4 per million person-years between 1994 and 2013. The incidence was 4.7 times higher in women than in men, was not influenced by socioeconomic status, and has remained stable over the 20 year study period. The peak age of onset was 55–69 years. Survival at 1, 5, and 10 years was 94.2, 80.0, and 65.7%, respectively. The prevalence was 307 (290–323) per million with the highest prevalence in the 70–84 years age group. We estimate there are currently 1180 new cases of systemic sclerosis each year in the UK, and 19,390 people living with systemic sclerosis. Due to the predicted growth and aging of the population, we predict a 24% increase in incident cases and 26% increase in prevalent cases in 20 years’ time. Our estimates of incidence and prevalence are higher than previously reported in the UK, but similar to recent USA and Swedish studies, and do not support a north-south gradient of the occurrence of systemic sclerosis in Europe.
format Online
Article
Text
id pubmed-6061074
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-60610742018-08-09 The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink Royle, Jeremy G. Lanyon, Peter C. Grainge, Matthew J. Abhishek, Abhishek Pearce, Fiona A. Clin Rheumatol Original Article To estimate the incidence, prevalence, and survival of systemic sclerosis in the United Kingdom. We conducted a historical cohort study using data from the Clinical Practice Research Datalink (CPRD). We calculated the incidence and survival of systemic sclerosis between 1994 and 2013 and examined its association with age, sex, and socioeconomic status. We calculated point prevalence on 1 July 2013 and examined its association with the same exposures. We identified 1327 cases with incident systemic sclerosis. Annual incidence was 19.4 per million person-years between 1994 and 2013. The incidence was 4.7 times higher in women than in men, was not influenced by socioeconomic status, and has remained stable over the 20 year study period. The peak age of onset was 55–69 years. Survival at 1, 5, and 10 years was 94.2, 80.0, and 65.7%, respectively. The prevalence was 307 (290–323) per million with the highest prevalence in the 70–84 years age group. We estimate there are currently 1180 new cases of systemic sclerosis each year in the UK, and 19,390 people living with systemic sclerosis. Due to the predicted growth and aging of the population, we predict a 24% increase in incident cases and 26% increase in prevalent cases in 20 years’ time. Our estimates of incidence and prevalence are higher than previously reported in the UK, but similar to recent USA and Swedish studies, and do not support a north-south gradient of the occurrence of systemic sclerosis in Europe. Springer London 2018-06-30 2018 /pmc/articles/PMC6061074/ /pubmed/29961234 http://dx.doi.org/10.1007/s10067-018-4182-3 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Royle, Jeremy G.
Lanyon, Peter C.
Grainge, Matthew J.
Abhishek, Abhishek
Pearce, Fiona A.
The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink
title The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink
title_full The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink
title_fullStr The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink
title_full_unstemmed The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink
title_short The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink
title_sort incidence, prevalence, and survival of systemic sclerosis in the uk clinical practice research datalink
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061074/
https://www.ncbi.nlm.nih.gov/pubmed/29961234
http://dx.doi.org/10.1007/s10067-018-4182-3
work_keys_str_mv AT roylejeremyg theincidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT lanyonpeterc theincidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT graingematthewj theincidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT abhishekabhishek theincidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT pearcefionaa theincidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT roylejeremyg incidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT lanyonpeterc incidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT graingematthewj incidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT abhishekabhishek incidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink
AT pearcefionaa incidenceprevalenceandsurvivalofsystemicsclerosisintheukclinicalpracticeresearchdatalink